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Abstract
The safety and effectiveness of medical devices are ensured by market-area-specific
laws and regulations. In 2017, the European Parliament and Council published a
new medical device regulation (MDR) that repealed the old medical device directives.
Considering usability, the regulation states that the device manufacturer must
eliminate or reduce the risks related to use errors as far as possible. Complex user
interfaces (UI) that have inadequate usability can cause use errors that can possibly
affect the safety of a patient or a user.
The goal of this master’s thesis was to research medical device regulation, update
the quality system of a company to comply with the new MDR considering usability,
develop a usability engineering (UE) process for the company according to usability
standard IEC 62366-1:2015 and apply the process for a new navigated transcranial
magnetic stimulation (nTMS) device.
The quality management system (QMS) of the company was updated by develop-
ing a new version of a standard operating procedure (SOP) for the UE process. The
UE process resulted in finding several use errors and hazards that could affect the
safety of a patient or a user. The usability evaluation performed for the new nTMS
device resulted in the identification of 17 usability findings that were mostly created
by unclear instruction texts and ambiguous GUI components.
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Tiivistelmä
Lääkinnällisten laitteiden turvallisuus ja tehokkuus turvataan markkina-aluekohtaisilla
laeilla ja asetuksilla. Vuonna 2017, Euroopan parlamentti ja neuvosto julkaisivat
uuden asetuksen lääkinnällisistä laitteista kumoten aikaisemmat lääkinnällisten lait-
teiden direktiivit. Käytettävyydestä asetus määrää, että laitteiden valmistajan on
poistettava tai vähennettävä käyttövirheistä johtuvia riskejä niin paljon kuin mahdol-
lista. Monimutkaiset käyttöliittymät puutteellisella käytettävyydellä voivat aiheuttaa
käyttövirheitä, jotka voivat vaarantaa potilaan tai käyttäjän turvallisuuden.
Tämän diplomityön tavoite oli tutkia lääkinnällisten laitteiden sääntelyä, päivittää
firman laatujärjestelmä lääkinnällisten laitteiden asetuksen mukaiseksi käytettävyy-
den osalta, kehittää käytettävyystekniikkaprosessi firmalle käytettävyysstandardi
IEC 62366-1:2015 mukaisesti ja soveltaa prosessia uuteen navigoituun transkraniaali-
seen magneettistimulaatiolaitteeseen (nTMS laite).
Firman laatujärjestelmä päivitettiin laatimalla uusi versio käytettävyystekniik-
kaprosessin toimintaohjeesta. Käytettävyystekniikkaprosessissa löydettiin useita
mahdollisia käyttövirheitä ja vaaroja, jotka voisivat vaikuttaa potilaan tai käyttä-
jän turvallisuuteen. Uudella nTMS laitteella suoritetussa käytettävyysarvioinnissa
tunnistettiin 17 käytettävyyslöydöstä, jotka johtuivat enimmäkseen epäselvistä ohje-
teksteistä ja käyttöliittymäkomponenteista.
Avainsanat Lääkinnällisten laitteiden asetus, lääkinnällinen laite, graafinen
käyttöliittymä, käytettävyys, käytettävyystekniikkaprosessi, IEC
62355-1:2015
iv
Preface
I want to express my gratitude to professor Risto Ilmoniemi for supervising my thesis
and having time to comment on my writing. I want to thank my advisor Markus
Paasi for his excellent guidance and help throughout the thesis. A big thank you
also to my awesome colleagues at Nexstim for answering my questions and bringing
joy to my work days. I would also like to thank all the clinical professionals who
participated in my usability study.
Studying at university would have been a lot harder without my dear friends and
fellow students. Thank you for your help with long days of studying and all the joy
you brought me after school. Finally, I would like to express my endless gratitude to
my mom and dad for their support and encouragement throughout my studies.
Helsinki, 21.02.2020
Melissa Holopainen
vContents
Abstract ii
Abstract (in Finnish) iii
Preface iv
Contents v
Abbreviations vii
1 Introduction 1
2 Background 3
2.1 Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.2 Transcranial magnetic stimulation . . . . . . . . . . . . . . . . . . . . 3
2.3 Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.4 New Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
3 Medical device regulation 9
3.1 European Union . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
3.2 United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
3.3 Canada . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
3.4 Other areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
4 Usability standards 14
4.1 IEC 62366-1:2015 Application of usability engineering to medical devices 14
4.1.1 Requirements of the usability engineering process . . . . . . . 15
5 The quality system of the company 17
5.1 Updating the quality system . . . . . . . . . . . . . . . . . . . . . . . 18
6 Results of the usability engineering process 19
6.1 Use specification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
6.1.1 Intended medical indication . . . . . . . . . . . . . . . . . . . 19
6.1.2 Intended patient population . . . . . . . . . . . . . . . . . . . 19
6.1.3 Intended part of the body and tissue interacted with . . . . . 20
6.1.4 Intended user profile and use environment . . . . . . . . . . . 20
6.1.5 Operating principle . . . . . . . . . . . . . . . . . . . . . . . . 21
6.2 User interface characteristics and potential use errors related to safety 21
6.2.1 Risk screening . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
6.2.2 Task analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
6.3 Risk analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
6.4 User interface specification . . . . . . . . . . . . . . . . . . . . . . . . 27
6.5 User interface design and implementation . . . . . . . . . . . . . . . . 29
6.6 User interface evaluation . . . . . . . . . . . . . . . . . . . . . . . . . 30
vi
6.6.1 Formative evaluation . . . . . . . . . . . . . . . . . . . . . . . 30
6.6.2 Summative evaluation . . . . . . . . . . . . . . . . . . . . . . 34
7 Usability evaluation 36
7.1 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
7.1.1 Test system . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
7.1.2 Participants . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
7.1.3 Use scenarios . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.1.4 Data collection methods . . . . . . . . . . . . . . . . . . . . . 38
7.1.5 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
7.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
7.2.1 Scenario completion . . . . . . . . . . . . . . . . . . . . . . . 40
7.2.2 Identified usability findings . . . . . . . . . . . . . . . . . . . . 41
7.2.3 Questionnaire and interview . . . . . . . . . . . . . . . . . . . 42
7.2.4 Meeting the usability goals . . . . . . . . . . . . . . . . . . . . 45
8 Discussion 46
9 Summary 48
A Use scenarios and tasks 54
B Usability findings 56
vii
Abbreviations
3D Three dimensional
AAMI Association for the Advancement of Medical Instrumentation
AMID Active Implantable Medical Devices Directive
CE Conformité Européenne
DHF Design history file
DHR Device history record
DLPFC Dorsolateral prefrontal cortex
DMR Device master record
E-field Electric field
EU European Union
EMG Electromyography
FDA Food and Drug Administration
GUI Graphical user interface
IEC International Electrotechnical Commission
ISO International Organization for Standardization
IVDD In Vitro Diagnostic Directive
MCE Moderate critical error
MDAA Medical Device Amendments Act
MDD Medical Device Directive
NCE Non-critical error
MDR Medical Device Regulation
MFC Microsoft Foundation Class Library
MR Magnetic resonance
MRI Magnetic resonance imaging
MT Motor Threshold
NBT Navigated Brain Therapy, product name for the company’s thera-
peutic device
NBS Navigated Brain Stimulation, product name for the company’s di-
agnostic device
nTMS Navigated TMS
POI Point of interest
PMA Pre-market approval
PMS Post-market surveillance
QA&RA Quality Assurance and Regulatory Affairs
QML Qt Modeling Language
QMS Quality management system
rTMS Repetitive TMS
SNBT Smart Navigated Brain Therapy, product name for the company’s
new device the UE process is applied for
SOP Standard operating procedure
TMS Transcranial magnetic stimulation
TPD Therapeutic Products Directorate
UI User interface
UE Usability engineering
US United States
WHO World Health Organization
1 Introduction
Development of modern medical technology started in the first half of the 19th
century and since then the number of devices has increased rapidly and they have
become an essential part of health care [1]. For the first 100 years, there were no
regulation and fraudulent and dangerous devices were marketed. In the beginning of
the 20th century in the United States (US), the Pure Food and Drugs Act was signed
into a law eventually leading to the creation of the Food and Drug Administration
(FDA) and medical device regulation. [2] Similarly, other countries have established
their own regulations and have assigned authorities to ensure the safety of patients
and people using medical devices.
Medical devices are regulated to ensure the effectiveness and safety of such devices.
In the US, the FDA is the regulatory authority that supervises that medical devices
entering the US market obey the national laws. Before a new medical device can
be released to the market, it needs to get approval from the supervising authorities.
Before the 1990, all European countries had their own way of regulating medical
devices [3]. However, in 1990s, the Council of the European Union introduced three
directives to harmonize the complex regulatory systems in the European Union (EU)
[4, 5, 6].
In 2017, a new regulation on medical devices was adopted in EU replacing existing
directives. Along with other requirements, the medical device regulation states that
medical devices shall be designed and manufactured in such way that they are safe,
effective and suitable for their intended purpose. Risks related to medical device use
errors should be eliminated or reduced as far as possible. [7]
Laws and regulations are often hard to comprehend and thus, several organizations
have written standards that comply with the regulations. A harmonized standard
is a standard that is recognized by regulatory authorities to provide conformity to
regulations. It is not obligatory to follow standards, but they can be used to prove
the requirements of regulations. Standards often list the deliverable information a
manufacturer needs to provide. The obligation of the usability requirements of the
new medical device regulation (MDR) can be proven by applying two harmonized
standards recognized by the EU and the FDA.
Nowadays, medical devices are used not only in hospitals but also in private
practices and at home. As the use environment changes, also the users vary from
different health care professionals to patients themselves. The usability of a medical
device is an important factor to ensure correct use and safety of the user and the one
receiving the treatment. Complex medical devices that have inadequate usability
can cause use errors that possibly lead to dangerous situations. [8]
Navigated transcranial magnetic stimulation (nTMS) is an advanced technology
used, for example, for presurgical mapping of patient’s brain areas and treatment of
depression. Navigated TMS devices have traditionally been quite complex to use
and hard to learn. The company for which this master’s thesis is conducted for is
developing a next-generation nTMS device that will emphasize usability.
The purpose of this master’s thesis is to
2• research the medical device regulation in different market areas
• update the quality system of the company developing and manufacturing nTMS
devices to the level of the new MDR considering usability requirements
• develop a usability engineering (UE) process for the company according to the
two above mentioned harmonized standards
• apply the UE process for the company’s new nTMS device
The standards cover the usability of the whole user interface including the
physical aspects of the medical device as well as the software. As software is the new
component of the nTMS device under development, the focus of this master’s thesis
is on the usability of the software although the UE process is applied to the whole
user interface.
In this master’s thesis, the background of the company, TMS and the device
the usability engineering process is applied to are given in Section 2. The medical
device regulatory systems of the most significant market areas of the device are
presented in Section 3. In Section 4, a detailed description of the applied usability
standards is given. Section 5 describes the quality system of the firm and how it
was updated to comply with the new MDR. Results of the UE process are gone
through in Section 6 and Section 7 emphasizes the usability evaluation performed in
the process by presenting detailed description of the methods and obtained results.
Further development ideas of the device and future tasks are discussed in Section 8
and the thesis is summarized in Section 9.
32 Background
This chapter gives a background of the company the usability engineering process is
applied to, the nTMS technology the firm is using and existing and new products of
the company.
2.1 Company
The company for which the usability engineering process is applied is an incorporated
medical device firm that is registered and based in Finland. Nexstim designs,
manufactures, markets, sells, and services non-invasive navigated brain stimulation
products of the central nervous systems for therapeutic and diagnostic purposes.
Nexstim Plc is a parent company of the group and they share headquarters in
Helsinki, Finland. In addition to the parent company, the group has assigned sales
and service responsibilities to the fully owned affiliates Nexstim Inc in the US and
Nexstim GmbH in Germany. Nexstim Inc. acts as an importer and distributor in
the US.
The enterprise is publicly listed on both Nasdaq First North Growth Market
Finland and Nasdaq First North Growth Market Sweden following an initial public
offering in November 2014. The company relies on the unique nTMS technology and
has over 70 patents and pending patent applications. The key market areas are in
Europe, the US and Canada.
2.2 Transcranial magnetic stimulation
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method
introduced in 1985 by Barker and colleagues [9]. In TMS, a strong electric current is
fed into a round or figure-eight-shaped coil that is placed over the patient’s head.
The coil generates a pulsed magnetic field that induces an electric field (E-field)
inside the brain. [10] The E-field affects the transmembrane potential of the neurons
and consequently, the voltage-sensitive ion channels in the nerve cells [11]. Opening
of the ion channels may lead to depolarization of the neurons which in turn leads
to action potentials. Action potentials are signals that propagate inside neurons
activating other neurons or muscles. [10]
TMS can be navigated or non-navigated. In non-navigated TMS, the coil is
positioned over THE patient’s head based on the shape of the head surface and
locations of the eyes, ears, and nose. The disadvantage of non-navigated TMS is
the lack of knowledge of the stimulation location. In navigated TMS, different
technologies are used in order to show the stimulation location on the brain. There
are two types of navigated TMS: line-navigated and E-field-navigated. In line
navigation, the stimulation coil is placed over the target area based on the patient’s
individual magnetic resonance (MR) images. It is assumed that the maximal E-field
will be located on a line at the center of the coil perpendicular to the coil surface.
However, line navigation can lead into inaccurate stimulation location, if the coil
is not positioned optimally in respect of the skull. In E-field-navigated TMS, in
4addition to the location information gained from the MR images, the patient’s head
geometry is also taken into account when calculating the E-field location and strength.
[10] A visualization of the E-field and line-navigated TMS are presented in Figure 1.
Figure 1: Difference between the navigation point location obtained using E-field
navigation and line navigation. The image on the left side presents the E-field-
navigated stimulation point and the E-field maximum at the same location. The
image on the right side presents the line-navigated stimulation point and the actual
location of the E-field maximum in slightly different locations. [10]
E-field navigation can be obtained when technical parameters of the stimulating
coil and physical parameters of the patient’s head and brain are known. Required
coil parameters include location, orientation, tilt, size, and shape of the copper
windings. Physical parameters of the patient’s head can be obtained from an
magnetic resonance image (MRI) scan that includes the whole head. Knowledge of
the above parameters needs to be combined by performing a registration where the
patient’s head coordinates are aligned with the MRI’s coordinates (Figure 2). When
the head tracker and coil are in the camera’s field of view, their locations are known in
the camera coordinate system. Anatomical landmarks in relation to the head tracker
are marked with a registration pen to the camera coordinate system. When the same
landmarks are marked to the MRI scans, a registration algorithm can combine the
MRI and camera coordinate systems. After the registration is performed, measuring
the coil location in relation to the head tracker enables showing E-field location in
the 3D reconstruction of the patient’s MR images.
5Figure 2: Electric field navigation [10]
2.3 Products
Nexstim Plc produces nTMS devices both for diagnostic and therapeutic applications.
The diagnostic device called NBS is used for pre-surgical mapping of the speech and
motor cortices of the brain. The brain is a plastic organ and functional areas can
move into different locations when a tumor grows inside the brain [10]. Structural
brain scans can not reveal the location of functional brain areas, and therefore
nTMS is needed. Mapping the brain with nTMS gives knowledge of the locations
of functional areas and thus makes surgery planning easier and safer. In mapping,
hundreds of stimuli are given to the area close to the tumor or other areas of interest
and electromyography (EMG) or speech tracking is used to find out, if stimulation
excites a response in that area. The excitatory and inhibitory stimuli are marked to
the MRI scans making a map representing safely operative brain areas and areas
that should be preserved.
Nexstim’s NBS product was Conformité Europeénne (CE) marked in 2003 to
enable sales and marketing in Europe. Six years later the Food and Drug Adminis-
tration (FDA) in the United States (US) approved the device. The latest approval
for the diagnostic device was received from Health Canada in December 2019.
The therapeutic device, NBT, is used for the treatment of major depressive disorder
and chronic neuropathic pain. About 30% of major depressive disorder patients fail
to respond to standard medication treatment [12] and therefore alternative treatment
methods are needed. Functional brain imaging has shown reduced activity in the
dorsolateral prefrontal cortex (DLPFC) of patients suffering from depression [13] [14].
The nTMS depression treatment stimulates the DLPFC at 10 Hz or 50 Hz frequency
6to increase its activity.
The medical treatment of neuropathic pain is far from optimal, as less than
half of the patients get satisfactory pain relief from traditional treatment. It has
been studied that high frequency rTMS stimulation of the primary motor cortex
contralateral to the pain has analgesic effects. [15]
The intensity of the treatment is determined individually for each patient by
finding out a threshold intensity at which a muscle responds to the stimulation. In
pain therapy, the muscle is at the pain site and in depression therapy, it is typically
a thumb muscle. The threshold intensity is determined by attaching EMG electrodes
to the tracked muscle and giving pulses to the representative area in the brain motor
cortex. A motor threshold algorithm detects responses and iterates the intensity to
be the minimum value at which the muscle reacts to the stimulus. The stimulation
intensity in treatment is determined as % of the motor threshold which makes the
treatment individual for each patient.
In Europe, the NBT device was CE marked for the treatment of major depressive
disorder and chronic neuropathic pain in 2012. The therapeutic device got FDA
clearance for the treatment of depression in early 2018, enabling marketing and
commercial distribution of NBT in the US. In 2019, NBT got a Health Canada
license for treatment of depression.
Both of the company’s devices consist of a TMS stimulator, figure-eight-shaped
stimulation coil, coil holder, camera, EMG, workstation PC and display, foot pedal,
patient chair, head tracker and digitize pen. In addition to those components, the
diagnostic device contains an additional PC display and a speech mapping module,
if speech license is purchased. Figure 3 presents the therapeutic device.
Figure 3: Nexstim’s Navigated Brain Therapy (NBT) system.
72.4 New Product
The NBT system introduced earlier is Nexstim’s first product targeted for therapy
use. Its software is heavily based on the pre-surgical device software which is clearly
seen in the graphical user interface (GUI). The GUI of NBT is presented in Figure
4. In NBT, everything can be done on one screen and the software does not give
any hints on what the user should do next. As the depression market has grown,
the typical user is not a researcher used to technical equipment but for example a
psychiatrist. This has led to long training times and extensive usage of training
resources.
Figure 4: Graphical user interface of NBT software.
Now, the company’s aim is to develop the next-generation of therapy product
that is specifically intended for the treatment of major depressive disorder and
chronic neuropathic pain. The new product will have a completely new, modern
and workflow-driven GUI that can be operated from a touch screen. The depression
workflow will be as straightforward as possible and designed only for the most basic
use. The pain workflow will be slightly more open and suitable also for research
purposes. In the first release, the GUI will be in English, but later it can possibly be
localized to different languages. The aim is that the product will be easy-to-learn
and easy-to-use. In this thesis, the new product will be called SNBT standing for
smart navigated brain therapy.
In the development phase, the company specified usability goals for the new
product. From the user’s perspective, the system should have a guided process that
minimizes mistakes and supports natural and easy workflow. Thus, the first usability
goal was that the user must know what to do next. The user should be able to
follow the right workflow path without mistakes or major error button pushes. The
8second goal was that the user must be able to use the system from two different
distances: by the workstation and by the patient. In several workflow steps the user
is standing by the patient and needs to hear and see information without walking to
the workstation.
For the customer, product simplicity and treatment effectiveness create resource
efficiency. That is why the third usability goal was that treatment session should be
carried out in less than one hour. The fourth goal was that the user shall be able to
measure the quality of a treatment.
For Nexstim, the new product could amplify predictable sales and reduce the role
of technical support in troubleshooting problems. The fifth goal was that user can
explain verbally on what state the GUI is in and can troubleshoot on their own. The
sixth goal was to decrease the time the system was not used by customers. That can
be achieved, for example, by user knowing when their coils will expire and when to
order yearly maintenance.
The new product will be CE marked and it shall meet the requirements that are
needed for FDA’s pre-market approval (510k). The approval processes are explained
in Section 3.
93 Medical device regulation
This section presents the outline of medical device regulations in different market
areas. Medical devices are regulated by national governments and international
authorities to give the best possible treatment for patients. The control ensures that
that no compromises are made in the safety, performance, or effectiveness of medical
devices. The EU, US, and Canada regulations are in focus in this section as those are
the target market areas of the new product. A data gathering table of the medical
device regulation in the target areas is presented in Table 1.
3.1 European Union
Before 1990, all EU member countries had their own way of regulating medical
devices [3]. In the 1990s, the Council of the European Union introduced three
directives to harmonize the complex regulatory systems. The 1990 directive, AIMD
90/385/EEC, considered the legislation of active implantable medical devices, the
1993 directive, MDD 93/42/EEC, concerned medical devices, and the 1998 directive,
IVDD 98/79/EC, in vitro diagnostic devices [4, 5, 6]. In 2017, the European
Parliament and Council published Regulation 2017/745 on medical devices (MDR)
and Regulation 2017/746 on in vitro diagnostic medical devices, repealing the previous
three directives [16, 17]. The regulations do not have to be made into national laws
unlike directives, and thus, the risk of different interpretations is reduced across the
member countries. The new MDR has the same basic regulatory requirements as
the old directives, but there are new requirements as well.
The MDR defines the "general requirements" to ensure the safety and effectiveness
of a medical device whereas the old medical device directive required only safety and
performance as described in the intended use of the device. The MDD and MDR
both require manufacturers to conduct post-market surveillance (PMS), but MDR
provides detailed requirements for the PMS. [5, 16] Considering usability, the general
requirements of MDR state that the risks related to use error shall be eliminated or
reduced as far as possible.
The MDR entered into force on May 26th, 2017 with a transition period of three
years. From 2020, all new CE mark requests need to be delivered according to the
new regulation, and CE marks delivered under the old directives can be valid until
2024. [16]
EU member states designate a governmental body called the Competent Authority
to supervise the implementation of the MDR. The Competent Authority in Finland
is Fimea. When a device fulfills the general requirements and the manufacturer
has declared conformity with the MDR, a CE mark can be placed on the device.
After earning the CE mark, the medical device can be marketed in all EU member
countries. [16]
The MDR classifies medical devices into four risk-based classes (I, IIa, IIb, III)
that have different demands to prove the conformance with the general requirements.
Class-I devices are simple in design and pose extremely little risk of harm. [3] Class-I
devices are further divided into sterile (Is), measuring (Im), reusable surgical (Ir) and
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non-sterile, non-measuring or non-reusable surgical device classes [16]. Examples of
different Class-I devices include scalpels for Ir, examination gloves for Is, stethoscopes
for measuring and knee supports for non-sterile, non-measuring and non-reusable
surgical. The manufacturers of all Class-I devices need to implement quality man-
agement system (QMS) and provide technical documentation that provide detailed
information about the device. The QMS can be established by applying harmonized
standard ISO 13485 Medical devices – Quality management systems – Requirements
for regulatory purposes [18]. After the required documentation is done, the non-
measuring, non-sterile or non-reusable surgical Class-I device producer prepares a
declaration of conformity and is allowed to place a CE marking on the device. The
QMS and technical file of the special Class-I devices need to be audited similarly as
Class-II devices presented below. [16]
The conformity assessment of higher risk devices is overseen by Notified Bodies
designated by the Competent Authorities. Notified Bodies are companies that
specialize in evaluating products for CE marks. Class-IIa devices, such as endoscopes
and powered wheelchairs pose a relatively low risk to the human body. Nexstim’s
NBS and NBT devices are in Class-IIa. Class-IIb products are medium to high-risk
devices such as dialyzers, and orthopedic implants. [3] For the conformity assessment
by a Notified Body, the company producing Class-II devices needs to provide technical
documentation and implement the QMS [16]. If the assessment is successful, the
Notified Body will issue a CE marking certificate for the device and a certificate of
conformity for the manufacturer for complying with the quality requirements. The
manufacturer of Class-II device needs to have the certificate before they can declare
conformity with MDR.
Class-III products, such as aneurysm clips and artificial heart valves, pose a high
risk to the human body [3]. For the conformity assessment, the Class-III device
manufacturer needs to provide the same documentation as for Class-II devices. In
addition, implantable Class-II devices and all Class-III devices require clinical inves-
tigation to prove the safety and performance requirements. The clinical investigation
can be avoided if the device is equivalent to an already marketed device. In that
case, the equivalence needs to be demonstrated to the Notified Body. [16]
3.2 United States
In the US, the safety of food and drugs became under regulation for the first time in
the signing of the Pure Food and Drugs Act in 1906. This led to the establishment
of the supervising authority FDA in the same year. The Act defined medical devices
as drugs, but the requirements for drugs were not sufficient to assure the safety of
devices. The definition of a medical device was added when the Act was modernized
into the Federal Food, Drug, and Cosmetics Act in 1938. The 1938 Act entitled the
FDA to bring charges against devices that were unsafe but no pre-market actions
were required. [2]
With Medical Device Amendments Act (MDAA) approved in 1976, the FDA was
finally justified to regulate the products prior to going to the US market. [19] The
MDAA stated that manufacturers need to provide assurance that the medical devices
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are both safe and effective [20]. The MDAA classified medical devices into three
risk-based classes. Class-I devices present minimal risk of harm and are simple in
design. [19, 21, 22] Class-I products include, for example, stethoscopes and surgical
instruments. The regulatory pathway for Class-I devices is the easiest. The safety
and effectiveness of Class-I devices can be ensured by so-called general controls.
General controls include provisions of misbranding, adulteration, device banning,
pre-market notification and so on [20]. However, most Class-I products are exempt
from the pre-market notification [3, 22]. The FDA requires manufacturers of all
medical devices to apply federal regulation 21 Quality System Regulation, but some
Class-I devices are excluded from the process [23].
Class-II devices, such as computed tomography scanners, have a moderate risk
of harm. Nexstim’s NBS and NBT devices are in Class-II. For them, the general
controls are not sufficient enough to prove the safety and effectiveness. Class-II
devices are subject to special controls, which include performance standards, post-
market surveillance, patient registries, special labeling requirements, pre-market
data requirements, and guidelines. [24] Pre-market notification, better known as a
510(k) submission, is required for the Class-II devices. In the 510(k) submission,
the manufacturer needs to demonstrate that the product is substantially equivalent
to a previously cleared device. [3, 21, 22] Substantially equivalent devices have the
same intended use, technical characteristics, and safety and effectiveness. Additional
clinical data is usually not required for a 510(k) submission. Most new medical
devices proceed to market through the 510(k) process. [3, 22]
Class-III devices have the highest risk of illness or injury and are therefore subject
to the strictest regulation controls. Class-III devices include risky, completely new,
and/or life-supporting devices, such as pacemakers and silicone breast implants.
For Class-III devices, the general and special controls are not enough to prove that
the device is safe and effective for its intended use. In addition to the controls,
Class-III devices require pre-market approval (PMA) from the FDA. In PMA, the
manufacturer demonstrates the safety and effectiveness of the device through clinical
studies. [3, 21, 22, 25] All devices without a predicate are classified as Class-III
devices even though the risk might be low. The manufacturer of the device can
request for reclassification into Class-I or Class-II through the De Novo process.
[3, 26] There are two requirements for devices seeking for the De Novo requests. The
device can not belong to a device type that has previously been classified and the
general or special controls need to be sufficient to prove the safety and effectiveness
of the device [22]. De Novo devices are exempt from the PMA process, but 510(k)
might be required.
3.3 Canada
In Canada, medical device quality, safety, and effectiveness requirements are defined
by the Food and Drug Act and medical device regulations [27]. The medical device
regulation authority in Canada is Health Canada working under the health ministry.
Inside Health Canada are several branches and operational directorates of which
Therapeutic Products Directorate (TPD) is responsible for medical devices. The TPD
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supervises that medical devices entering the Canadian market fulfill the requirements
of the Food and Drug Act and regulations. [28]
The classification of medical devices is similar but not identical to the classification
system in the EU. The classification is risk-based and has four classes: I, II, III,
IV. [28] Before marketing in Canada, the manufacturer of Class-I device needs to
apply for an Establishment Licence. Manufacturers of Class-II, III, IV devices need a
Medical Device Licence before they can market and sell their device in Canada. As in
the approval processes in other countries, the number of requirements varies between
device classes. [29] One requirement for the Class-II, III and IV device manufacturers
is to implement QMS according to ISO 13485 and additional requirements from
Canadian Medical Device Regulation. The requirements for Class-II devices are
equivalent to the 510(k) in the US and Class-IV requirements equivalent to PMA.
In Canada, Nexstim’s NBS product is classified into Class-II as it is an active
diagnostic device intended to image physiological features. Active therapeutic devices
intended to administer energy to the patient’s body are typically classified into
Class-II, but as the company’s NBT device could be potentially hazardous, due to
the repetitive TMS pulses, it is labeled into Class-III.
3.4 Other areas
In 2010, the World Health Organization (WHO) reported that approximately 30%
of countries have a framework for regulating medical devices, 30% have partial
regulation and the rest are developing a system or do not have any regulation [30].
As the global interest in medical devices has increased and many countries still lack
regulatory frameworks, WHO developed a model of a global regulatory framework
for medical devices and in vitro diagnostic devices. [31] The publication aims to
guide countries in develop a regulatory system.
As in the EU, the medical device regulation is the same in all member countries,
most of the non-EU countries have their own regulations and approval procedures
that have been developed before WHO’s guidelines. Some countries have approved
international regulations and standards, but they still might have additional laws
and rules that are not in line with international regulations.
For example, in Australia, Therapeutic Goods (Medical Devices) Amendment
Regulation was originally based on the EU directives on medical devices, but as it
has been further developed, it now contains several differences. The risk-based device
classification is similar to the EU one, but it has five classes. Class-I for non-sterile
and non-measuring devices, Class-II for sterile and measuring, and Classes IIa, IIb,
and III. The quality management system required for other devices than Class-I is
based on the international standard ISO 13485. [28]
Some countries, such as Brazil, require manufacturers to have a local distributor
or representative that is responsible for issuing applications and technical documents
to the authorities. In Brazil, the device classes are I, II, III, and IV which are similar
to those in the EU. Devices in classes I and II have two possible regulatory pathways.
"Cadastro" is the faster and easier procedure for low risk devices that have been
separately listed in Brazilian medical device law. "Registro" is a more demanding
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pathway for high risk devices. Class-III and IV devices have to go through the
Registro pathway and an audit to get a Brazilian Good Manufacturing Practices
certificate. In Registro procedure, manufacturers need to provide full technical
documentation and in some cases also clinical data. All documents have to be
written in Brazilian Portuguese. [28]
In China, the medical device regulation field is quite complex and different
provinces might have different practices. The classification system is similar to the
EU, but it only has three classes. A device manufacturer needs to provide a quality
certificate according to the international quality management standard, ISO 13485.
Before approval, Class-II and III devices need to be tested in Chinese test laboratories
and clinical studies performed in China might also be required. All documentation
for the application needs to be provided in simplified Chinese. [28]
Region Legislation Implementation
of QMS
Device Classes Regulatory Au-
thority
US Medical
Device
Amend-
ments Act
(MDAA)
FDA Quality sys-
tem regulation
I, II, III FDA
EU Medical
Device
Regulation
ISO 13485 stan-
dard
I, Is, Im, Ir, IIa,
IIb, III
Notified Body
designated by
national Compe-
tent Authority
Canada Food and
Drug Act
ISO 13485 +
specific require-
ments
I, II, III, IV TPD under
Health Canada
Table 1: Summary of medical device regulation in the US, EU and Canada.
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4 Usability standards
The regulation of medical devices has improved over the years but they have not
been safe enough and use errors of such devices became a frequent concern. In
1993, the first national usability standard for medical devices was published by
the Association for the Advancement of Medical Instrumentation (AAMI) in the
USA. The standard, AAMI HE48:1993 Human Factors Engineering Guidelines and
Preferred Practices for the Design of Medical Devices, adopted the usability guidelines
of an existing standard, MIL-STD-1472 – Human Factors Engineering, written for
military equipment. The medical device usability standard covered introduction and
guidelines to human factors design. [32]
In 2001, AAMI published a new standard partially replacing the 1993 guidelines.
The AAMI HE 74:2001 Human factors design process for medical devices, focused
on the user-centered process that was linked to the requirements set by the FDA.
This standard was later adopted by the International Electrotechnical Commission
and released as IEC 60601-1-6:2004 Medical electrical equipment – Part 1-6: Gen-
eral requirements for safety – Collateral standard: Usability. [32] Since then, the
international standard has been updated three times and it has been separated into
two different standards: the IEC 60601-1-6 and IEC 62366 Application of usability
engineering process to medical devices [33].
IEC 62366 was originally published in 2007 to separate the usability engineering
process from the second edition of IEC 60601-1-6. In 2015, the second version of
IEC 62366 was issued. Both IEC 60601-1-6:2013 and IEC 62366:2015 standards are
valid today and approved in the EU, Canada and the US [34, 35, 36].
The IEC 60601-1-6:2013 describes the general requirements for medical device
safety. The standard states that "The medical electrical equipment shall provide
adequate usability such that the risks resulting from normal use and use error are
acceptable". [33] Here the medical electrical equipment denotes a medical device.
The second requirement of IEC 60601-1-6:2013 is that a usability engineering process
described in international standard IEC 62366-1:2007 shall be performed [33]. Since
then, the second version of the IEC 62366 standard has been published, but 60601-1-6
has not been updated to take that into account. The usability engineering process
described in this thesis is applied by the latest 2015 version of the IEC 62366.
4.1 IEC 62366-1:2015 Application of usability engineering
to medical devices
The IEC 62366 standard has two parts. Part 1, published in 2015, describes the
usability engineering process and part 2, published in 2016, gives guidance on how
to conduct the process. The usability engineering process is intended to identify
and minimize the use errors and thereby reduce use-associated risks. The standard
describes how a manufacturer should analyze, develop, and evaluate the safety-related
usability of the medical device. The general requirements of the standard state that
the process shall address not only the user interactions with the software but also, the
interactions related to device transport, storage, installation, operation, maintenance,
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repair, and disposal. As software is the new component of the new SNBT system,
the evaluation part of this master’s thesis focuses on software.
The standard requires the manufacturer to reduce the use-related risks by adapting
safety by design, implementing protective measures in the medical device itself or in
the manufacturing process or creating information for safety. Information for safety
includes a user manual, warnings, and labels on the device. The usability engineering
process needs to be applied also to the information for safety to determine that the
material is perceivable, understandable and supports correct use. The extent of the
process is determined by the complexity of the user interface (UI) and the severity
of the harm associated with the device.
4.1.1 Requirements of the usability engineering process
The usability engineering (UE) process lists multiple steps the manufacturer needs
to go through to prove that the medical device is easy to use. The steps of the UE
process are presented in Figure 5. The process requires the manufacturer to create a
usability engineering file that contains all documents delivered.
Clause 5.1 of IEC 62366:2015 states that the manufacturer must prepare a use
specification for the medical device. The use specification must include the intended
use of the medical device and definitions for a patient, user, and use environment.
The document needs to describe which part of the body or tissue type is interacted
with as well as the operating principle of the device.
Clause 5.2 of the standard requires the manufacturer to identify UI characteristics
and potential use errors related to safety. The characteristics shall be determined
by the application of risk analysis described in the risk management standard ISO
14971:2007. As part of the analysis, the producer shall identify known and foreseeable
hazards and hazardous situations that could affect the patient’s or user’s safety (Clause
5.3 in IEC 62366:2015). Clause 5.4 requires that the hazard-related use scenarios
and the severity of the associated harm need to be described. After all hazards
and risks arising from them have been analyzed, the manufacturer shall select the
hazard-related use scenarios for summative evaluation, known previously as usability
validation (Clause 5.5).
Technical requirements for the UI need to be specified according to Clause 5.6
of IEC 62366:2015. These requirements can include specification, for example, for
the character size on the screen and sound volume used in the UI. At this phase the
manufacturer needs to decide whether accompanying documentation and medical-
device-specific training is required.
The usability of the device needs to be tested through the development process
and after the product is ready to be marketed. The assessment done during the
development is called formative evaluation and the assessment done for the final
product is summative evaluation. Clause 5.7 requires the evaluation plans to doc-
ument the objective of testing, used methods and which part of the UI is being
evaluated. If usability tests are done, the plans should include a description of the
test environment and participants. It also needs to be determined whether the par-
ticipants need training before the test and is there any accompanying documentation
16
given to them during the evaluation. In addition to these, the formative evaluation
plan should document when in the UE process the assessment should be performed.
The summative evaluation plan shall specify criteria for determining whether the
information for safety is perceivable, understandable and supports correct use.
After the evaluation is planned, the manufacturer needs to design and implement
the UI (Clause 5.8). At this point, the accompanying documentation and training
material should be established. The formative evaluation is performed at different
implementation phases and the results are stored in the UE file. If use errors, hazards
or hazardous situations are discovered during the assessment, steps of the UE process
shall be repeated.
The final step of the UE process is to perform the summative evaluation for
the final UI (Clause 5.9). Data from the assessment shall be analyzed to identify
the consequences of all use errors emerged. If new use errors, hazards or hazardous
situations are discovered during the analysis, the manufacturer must re-enter the
UE process. If no new hazards are found, the company needs to determine whether
further improvements are necessary. If improvements are not necessary, it needs
to be reasoned. The final step is to determine the residual risk related to use and
evaluate it according to the risk management process defined by ISO 14971:2007.
Figure 5: Usability Engineering process determined in IEC 62366-1:2015. Some
parts of the usability engineering process give input to the risk management process
described in standard ISO 14971. [8]
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5 The quality system of the company
This Section presents the quality management system of the company for which the
UE process is applied and describes how the system was updated to comply with
the new MDR.
The fundamentals and guidelines for Nexstim’s quality management system and
business are defined by the company’s quality policy and values. The policy aims
to assure that products and services meet the customers’ needs, are competitive,
are delivered to the customers as promised, and adhere to legal requirements and
applicable standards. The company’s internal values include economic efficiency,
innovativeness and personnel well-being. Customer values include efficiency and
reliability, confidence in products and processes, and customer satisfaction.
The quality policy and objectives are achieved by following the company’s quality
manual approved by the Head of quality assurance and regulatory affairs (QA&RA).
Nexstim’s QMS adheres to the requirements of the international ISO 13485:2016 Qual-
ity Management System standard, FDA Quality System Regulation, the European
Medical Device Directives and Regulation, Canadian Medical Device Regulations,
and Australian Therapeutic Goods Regulations. The European directives are com-
plied with until the firm’s QMS is refined to follow the new MDR in 2024 at the
latest. The quality system applies to the design, manufacturing, marketing, sales,
after-sales, and service of Nexstim’s medical devices.
The quality system of the company is divided into three document groups: quality
system documents, product-specific documents, and general quality system records.
The quality system documents create the backbone for quality by defining the quality
policy and manual and the operating instructions for performing different functions
for proofing excellence. Operating instructions, also known as standard operating
procedures (SOPs), describe the actions and documents the manufacturer needs
to provide to comply with, for example, a specific standard or a regulation. The
company’s SOPs include instructions, for example, for conducting a clinical evaluation
and performing a risk management process.
The application of the quality system produces multiple product-specific docu-
ments that need to be stored. The design history file (DHF) stores all documents
that are created through the development process of a product. DHF documents
include, for example, project plans, different level requirements for the product, and
test plans. The device master record (DMR) consists of the documentation needed to
manufacture the device. The DMR includes instructions, for example, for assembling
and packaging. Finally, the device history record (DHR) stores the documentation
generated during the manufacturing of an individual device. DHR demonstrates that
the device was assembled in accordance with the DMR.
The general quality system records are plans and reports of achieved results or
certifications of performed actions. The records include for example internal audit
reports, customer complaints, and training requirements for employees.
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5.1 Updating the quality system
In the earlier Section, it was presented that considering usability, the general require-
ments of the MDR state that the risks related to use error should be eliminated or
reduced as far as possible. The reduction of use errors can be shown by applying the
international harmonized usability standard IEC 62366 presented in Section 4.
In the company’s quality system, instructions for performing the UE process
described by the usability standard have been presented in an SOP Q310 Usability
Engineering Process established according to the first version of the standard. The
SOP has been outdated since the new version was published in 2015.
This thesis developed a new version of the SOP to comply with the newest version
of the standard. The new version of the UE process SOP lists the requirements of
the usability standard and the deliverable documents to prove accordance with each
requirement.
The documents resulting from the usability engineering process are stored in a
usability engineering file which is part of the products DHF except for user manual
and training material being part of the DMR.
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6 Results of the usability engineering process
This section describes the application of the usability engineering process for the new
product. The company manufacturing the device has performed the process before
for their existing devices, but it has been done according to the previous versions of
the IEC 62366 usability standard. In this thesis, the process was updated to meet
the requirements of the newest version of the standard.
6.1 Use specification
The use specification was created in collaboration with the company’s application
specialists, physician, and project assistant. The generated use specification is
presented in the following subsections.
6.1.1 Intended medical indication
The device will be used to treat major depressive disorder and chronic neuropathic
pain, thus the intended medical indication was specified separately for the two
applications. For the depression application, the system is intended to be used for
the treatment of major depressive disorder by targeting and delivering non-invasive,
repetitive, nTMS stimulation to the patient’s brain region called the dorsolateral
prefrontal cortex. The system is indicated to treat adult patients who have failed to
receive satisfactory improvement from prior antidepressant medication in the current
episode.
For the pain application, the system is intended to be used for the treatment of
chronic neuropathic pain by delivering non-invasive, repetitive, nTMS stimulation
to the patient’s motor cortex. The pain application is indicated to treat chronic
neuropathic pain in adult patients to alleviate pain.
6.1.2 Intended patient population
The intended patient population was decided to be adult patients who weigh less than
200kg. The weight limitation came from the technical specification of the patient
chair. For safety reasons, the device is not intended to be used with persons with
non-removable conductive, ferromagnetic or other magnetic-sensitive metal anywhere
in the head or within 30 cm of the stimulation coil. Using TMS with patients with
metal in the head is prohibited due to the attractive and repulsive forces generated
by the magnetic field that could move the metals [37].
Patients who have an active or inactive implanted device including deep brain
stimulators, cochlear implants, cardiac pacemakers, and vagus nerve stimulators are
not in the intended patient population because of possible heating and stimulation
of the devices. The devices could heat up due to the magnetic field induced eddy
currents in the conductive surface electrodes and implants. Heating brain tissue
above 43 ◦C can result in permanent damage. Furthermore, the implanted devices
could fire unintended stimulation, if voltages are induced to the electrode wires. [37]
20
The most serious adverse effect of rTMS is seizures, although the risk is minimal
[37]. Seizures are more dangerous to some people and therefore the device should not
be used with patients with increased intracranial pressure or serious heart disease
[38]. Several factors can also increase the risk of seizure. These factors include,
for example, substance abuse and intake or withdrawal of some drugs affecting the
nervous system [37]. That is part of the reason why TMS should not be used without
a clear benefit for patients suffering from other mental illnesses than depression.
The efficacy of rTMS therapy has not been proven with certain patient populations.
These include people suffering from seasonal affective disorder, substance-induced
depression, and depression secondary to a general medical condition. Several TMS
studies have excluded subjects that have not received satisfactory improvement
from antidepressant medication, have a recent suicide attempt or have a history of
unsatisfactory treatment with electroconvulsive therapy or vagus nerve stimulation.
The studies have included subject population aged 22 to 70 years and pregnant
women have been excluded. The depression treatment effectiveness can not be stated
for populations that have not been studied.
6.1.3 Intended part of the body and tissue interacted with
The TMS coil is placed on the patient’s scalp and the stimulation affects the tissues in
the scalp and cortical surface. The device contains an EMG system which electrodes
are placed on skin over muscle.
6.1.4 Intended user profile and use environment
The potential users of the device include psychiatrists, neurologists, nurses, hospitals’
biomedical engineers, and the technical support personnel of the manufacturer. The
users can be grouped as Users, including clinical personnel, Admin Users, including
hospitals’ biomedical engineer, and Service Users such as technical support personnel.
The users of the system shall interact with the device depending on their specific
roles. Some will be responsible for operating the device on patients, others will
execute administrative and service tasks on the system software and hardware.
All users shall have at least the following general skills: understand English, read
and understand the Latin alphabet and the westernized Arabic numerals and have
basic computer skills such as operating a touch screen, keyboard and mouse and
using external storage devices. The user is permitted to have mild vision and hearing
impairments, but the device is not intended to be operated by persons who are
pregnant, have any electrical implants or have conductive, ferromagnetic, or other
magnetic-sensitive metal implants anywhere in the upper body.
The level of education may vary between users, but only qualified medical per-
sonnel should use the device on patients. All users should go through at least the
initial device training.
The device is intended to be used in hospitals or other health facilities. The
system is movable within the same room and building.
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6.1.5 Operating principle
The system combines non-invasive TMS with MRI-based stereotactic navigation
and simultaneous surface EMG. The system uses stereotactic localization of the
stimulation coil to interactively visualize the calculated effects of TMS stimulation
and to guide TMS precisely over cortical areas.
6.2 User interface characteristics and potential use errors
related to safety
This section presents an analysis of the user interface characteristics and potential
use errors that could affect the patient’s or the user’s safety. The investigation was
done using two different techniques: risk screening and task analysis. Identifying
UI characteristics by going through a questionnaire was required by the usability
standard, but there were several options for analyzing possible use errors. Task
analysis was selected as it was the most analytic form of investigation suggested
by part two of the standard. The aim of the investigation was to find factors that
could be potential sources of injury or damage and that should be further evaluated
in the risk analysis presented in Section 6.3. In risk analysis, physical injuries and
damage to health or property are called harms and potential sources of harm are
called hazards.
6.2.1 Risk screening
The safety-related UI characteristics of the new product were screened by going
through the UI related questions in the risk management questionnaire described
in ISO 14971:2007 Annex C [39]. The purpose of the screening was to identify the
characteristics that could cause possible hazards and that should be further evaluated
in the risk analysis. The safety questionnaire contains a total of 34 questions of
which nine are UI related. The UI questions try to identify whether the successful
application of the device depends critically on human factors.
The successful use of the new SNBT device depends on the GUI design. Users
need to interpret displays correctly in order to treat patients and avoid use errors.
Weak GUI design can be a source of use errors.
Distractions during the use of a device can lead to use errors. However, the
company’s new product is meant to be used in a TMS room where disturbances are
untypical and thus the possibility of hazards arising from interruptions is minimal.
Connecting accessories to the SNBT device can create multiple possible hazards
if items are not connected properly. For example, attaching a damaged coil to the
stimulator can cause sparking and lead to the user being exposed to high temperatures
creating a risk of burn. However, connecting accessories is not related to the system
software and hence it is not further analyzed here.
The successful application of the new device includes using control interfaces
as the application must be operated via a touchscreen, mouse, keyboard, and foot
pedal. From these, the foot pedal is the most probable source of harm as it is used
to initiate stimulation.
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The SNBT device GUI displays information that needs to be interpreted correctly
to enable proper use of the system. The safety-related UI characteristics include
displaying electric field distribution, EMG responses, and coil positioning during
treatment. Misunderstanding data is a use error that could possibly lead to the
safety of the patient being compromised.
The new product has simple menus that will prevent the user from seeing the
underlying screen. In the main menu, the user can read the screen related contextual
help, take screenshots, adjust the sound volume et cetera. The possible hazards
arising from the menu design should be further analyzed.
The users’ background and skills play an important role when considering a
successful application of the new product. The intended users of the system are
described in the use specification presented in Section 6.1 and no potential sources
of harm should be created if the specification is followed.
The UI of the new system is used to initiate user actions and hence it is important
to display explanatory information to avoid use errors. One example of a UI initiated
action is that the GUI shows if the stimulation is not hitting the target. Then, the
user has to act and adjust the coil location.
Devices that depend on the essential performance of a function can cause great
risk of harm to the user’s or the patient’s safety if a fault arises. These kinds of
functions are, for example, alarms and life supportive devices display information.
The new device considered in this thesis does not depend on the essential performance
of functions and thus, it is not taken as part of the risk analysis.
The risk screening resulted in five GUI related points that should be taken into
account in the risk analysis. The GUI characteristics for the further analysis include
design features contributing to use errors, control interfaces, displaying information,
menu, and initiation of user actions from GUI.
6.2.2 Task analysis
Potential use errors that could affect safety were identified by conducting a task
analysis. Safety-related use errors are hazards that should be further analyzed in the
risk analysis. Task analysis is done by going through all the user interactions with
the medical device to develop an understanding of factors that could hinder user
performance. All functions of the device were vetted with the help of workflow charts
that had been formed earlier in the GUI development process. Using the system
involves several tasks and thus the task analysis was done separately for different
task levels.
Use cases presented in Figure 6 are the highest-level tasks in the system. It was
identified that from the use cases, only the following could lead to potential use errors
related to safety: perform examination and therapy in depression application, perform
examination and therapy in pain application, move the system to another room, clean
patient contact surfaces, and move the patient into and out of the chair. Furthermore,
when analyzing the lower-level tasks in these use cases, the use errors arising from
the software were identified to appear when performing examination and therapy
in depression and pain applications. The pain examination and treatment include
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almost the same set of sub-tasks and possible use errors as depression application
and therefore only the task analysis for depression application is presented below.
Figure 6: The use cases when using the system.
24
Perform examination and therapy in depression application: Perform ex-
amination and therapy for depression use case includes several sub-level tasks that
are presented in Figure 7. After analyzing, it was discovered that all other sub-level
tasks except for "Activate Head Tracker" could create software-related use errors
affecting safety.
Figure 7: The sub-level tasks in depression workflow.
In ’create new patient’ task, the user needs to select MRI for the patient, check
that the 3D reconstruction of the MR images is accurate, enter patient information
and set landmarks to the MR images. One possible use error is that the user could
select a wrong MRI for the new patient and hence the head 3D model would not
correspond with the actual head of the patient. Another safety-related use error is
that the user could select incorrect places for the MRI landmarks which could lead
to incorrect registration.
In ’load patient’ task, the user needs to select a patient, treatment plan and
whether the user wants to map the patient or give treatment. In addition, the user
can also create new treatment plans and review the maps and given treatments. Use
errors that could be made here include selecting the wrong patient, treatment plan
or active map. Selecting the wrong map as active could lead to delivering treatment
with too high or low intensity.
’Prepare patient’ includes sitting the patient into the treatment chair, attaching
EMG electrodes, and reviewing the EMG signal quality. Possible harm can be done
to the patient if the user selects the wrong EMG channel for the motor threshold
determination as then the treatment could be given with too low or high intensity.
Another possible use error is that the user mislabels the EMG channel so that it
does not correspond to the muscle the electrode is attached to. This could lead to
an incorrect map of the representation area of the muscle.
’Perform registration’ includes the following III-level tasks: set or reset MRI
landmarks, basic registration, and advanced registration. Set or reset MRI landmarks
involve the same possible use errors as the same task when creating patient. In basic
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registration, the user needs to point the MRI landmark locations in the patient’s head
with a registration pen. However, if the user points wrong locations, the registration
can be incorrect. In advanced registration, nine additional points are set to patient’s
head surface and careless work can similarly lead to incorrect registration.
In depression examination, the system operator needs to perform several tasks
including mapping the motor cortex and selecting a pulse from the map, determining
motor threshold (MT), and setting a treatment target. In all tasks involving stimu-
lation, a possible use error is to hold the coil poorly so that the bottom of the coil is
not tangentially positioned on the patient’s head. Holding the coil poorly could lead
to a too large area being stimulated and too high or low stimulation intensity due
to an incorrect MT result. Another use error is creating a wrong target for the MT
determination or for the treatment. Furthermore, the MT result could end up being
incorrect, if the determination process is prematurely terminated.
When giving treatment to the patient, the user needs to start and monitor the
treatment and view the treatment result. Optional tasks include re-determining MT,
pausing and stopping treatment and selecting and creating new treatment targets.
In addition to aforementioned use errors, giving treatment could result in the user
selecting wrong repetitive TMS (rTMS) sequence for the therapy and treatment
target not being reproduced. Insufficient treatment could be given if the stimulation
coil moves out of target or the treatment is stopped prematurely. Selecting a wrong
rTMS sequence can lead to stimulation with the wrong intensity and frequency.
Task analysis resulted in several possible use errors that could affect the patient’s
safety. These use errors are further analyzed in the next section.
6.3 Risk analysis
This section presents the risk analysis performed as required in the usability stan-
dard. The standard obligates the manufacturer to identify the foreseeable hazards,
hazardous situations and use scenarios leading to them that can arise from the UI
of the new product. Moreover, the severity of the harm that can emerge from a
hazard-related use scenario needs to be assessed.
The risk management standard ISO 14971 defines a hazardous situation as a
circumstance in which people, property or environment are exposed to one or more
hazards [39]. The severity of a harm is assessed using a five-point scale where 5
denotes catastrophic harm that results in death and 1 denotes negligible harm that
causes temporary discomfort or inconvenience. The severity scale is presented in
Table 2.
The risk analysis of the new SNBT product was conducted using the analysis of
the existing NBT device as a base. NBT uses almost the same hardware and most
of the software functions are the same although the graphical representation is not
identical. Thus, the hazards and hazardous situations arising from the two products
are similar. Some of the possible hazards and hazard-related use scenarios of the
new device were identified during the risk screening and task analysis presented in
Sections 6.2.1 and 6.2.2.
As described earlier, hazards are potential sources of harm and injury. Hazard
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Index value Severity Description
5 Catastrophic Results in death(s)
4 Critical Results in permanent impairment or life-
threatening situation, if medical intervention is
not obtained
3 Serious Results in injury or impairment requiring pro-
fessional medical intervention
2 Marginal Results in temporary injury not requiring pro-
fessional medical intervention
1 Negligible Temporary discomfort or inconvenience
Table 2: Severity scale used in risk analysis
can not lead to harm on their own unless a sequence of events creates a hazardous
situation. Hazard can be, for example, high temperature, but it does not cause a
skin burn unless a person sips hot tea and is exposed to the high temperature. In
this case, the use scenario is that a person sips hot tea, the situation is exposure to
the hot temperature, and the harm is a skin burn. Skin burn is a temporary injury
that does not require medical assistance and is hence ranked as severity level two.
In risk screening, it was evaluated that displaying important information is a
factor that should be further examined in the risk analysis. One example of a hazard
that can arise from displaying information is an attentional failure. If the use scenario
is that the EMG responses and coil position is not visible to the user when standing
next to the patient, the hazardous situation is that the system can not be used. In
this case, the harm is that the system is unusable, and patients can not be treated.
However, the severity ranking of this harm is only one as it will create only temporary
discomfort for the patient.
The task analysis discovered possible use errors that could create greater and
more severe harm. One example is in depression examination, where the user could
end the MT determination prematurely which could lead to too high stimulation
intensity due to too high MT. The hazard is that the patient is exposed to a magnetic
field and the hazardous situation is that the safe amount of stimulation is exceeded.
The harm that could arise from this situation is an epileptic seizure. Seizures are
ranked with severity level three as they are injuries that require professional medical
intervention.
The risk screening and task analysis revealed also completely new risks that
had not been discovered during existing systems risk analysis. In the new software,
the user must select a treatment plan from which she is giving treatment for the
patient. An attentional failure is observed if the user selects a wrong treatment plan.
The treatment plan contains the therapy targets and thus using the wrong plan
can lead to stimulation of unintended areas during the treatment. The hazardous
situation arising from this use scenario could be that the effect of the treatment
can be decreased as stimulation is not given to the right location. The possible
harm is ineffective treatment with a severity ranking of one, as it will only create
inconvenience for the patient.
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Another use scenario that had not been reported in the existing device’s risk
analysis is the user selecting the wrong rTMS sequence for the treatment. Incorrectly
selected rTMS sequence results in too high or low stimulation intensity and frequency.
If the parameters are too high, the hazardous situation is that the safe amount of
magnetic stimulation is exceeded, and if they are too low, the effectiveness of the
treatment can be decreased.
In total, the risk analysis resulted in over 120 risks related to usability and
from those around 50 were software-related. Some hazard-related use scenarios were
presented twice in the risk analysis as the same use scenario can lead to the amount of
magnetic stimulation being too high or low. Examples of analyzed risks are presented
in Table 3.
Hazard Use scenario Hazardous situation Harm Severity
Attentional
failure
Needed information
such as EMG re-
sponses and coil po-
sition during rTMS
therapy are not vis-
ible to user
User can not use the
system
System un-
usable
1
Magnetic
field
User ends MT de-
termination prema-
turely
Safe amount of mag-
netic stimulation ex-
ceeded in treatment
due to too high MT
value
Seizure or
equivalent
3
Attentional
failure
User accidentally
selects the wrong
treatment plan
causing stimulation
of unintended areas
Effect decreases due
to stimulation of the
wrong location
Ineffective
treatment
1
Attentional
failure
User selects the
wrong rTMS
sequence for treat-
ment
Effect decreases due
to stimulation with
too low frequency
Ineffective
treatment
1
Attentional
failure
User opens the
wrong patient
Safe amount of mag-
netic stimulation ex-
ceeded, stimulation
of unintended areas
Seizure or
equivalent
4
Table 3: Examples of risks evaluated in the risk analysis.
6.4 User interface specification
The usability standard requires the manufacturer to create user interface specification
that includes testable technical requirements relevant to the UI and an indication
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whether accompanying documentation and medical device-specific training is required.
Accompanying documentation is considered as part of the product and that is why
the UI requirements should include the specification for the user manual as well. In
addition, the content of the training material should also be defined.
The UI specification was written within the system requirements. The system
requirements include specifications for different hardware devices as well as the
software in general. The system’s usability requirements were written to ensure that
the usability goals presented in Section 2.4 would be met. Each goal generated one
to three requirements. The first goal was that the user must know what to do next.
This generated requirements for the workflow-driven GUI and screen headings that
describe what the user should do in the step.
The second goal, that aroused three requirements, was that the user must be able
to use the system from two different distances. The first requirement was that the
software shall give audio feedback during operations where it is likely that the user
does not look at the screen. The second requirement was that the software GUI shall
have big enough font size for information that the user needs to see when standing
next to the patient. The third requirement was that the software shall support using
the foot pedal in operations where the user is not at the workstation.
The third goal was that the treatment session should be carried out in less than
one hour. The longest approved depression treatment lasts for 37 minutes and thus
it was specified that opening data and preparing the patient shall be performed in
less than 20 minutes.
The ability to measure treatment quality was the fourth goal which generated
the requirement for the software GUI to present quality data after the treatment
is given. The requirement developed from the fifth usability goal was that each
screen shall have a unique heading to enable the user to know where one is in the
workflow process. The final goal considered decreasing system downtime and created
requirements for the system to inform the user about aging coils and approaching
yearly maintenance in advance.
The accompanying documentation of the new product includes the user manual
and a separate manual for the serviceman. The user manual of the existing NBT
system was used as guidance when writing the specification for the new manual.
The new product will have a traditional printed manual, as well as a software
integrated manual and a workflow step specific contextual help that can be read
from the workstation PC. The manual requirements list information that needs
to be presented. The content is specified to include information about the safety
aspects, used technologies and features, hardware devices and use instructions. For
example, the user manual shall include information about the intended use and
contraindications for using the system.
Like the user manual specification, the requirements for the training material
specify what should be trained to the user. The training material has been divided
into system training and application training. In system training, users are trained
to take care of the system’s daily maintenance and how to move the device as well
as about contraindications for use. Application training covers specific tasks that
users need to perform to treat patients.
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(a) (b)
(c) (d)
Figure 8: Color alternatives for SNBT GUI. The dark grey design presented in (a)
was chosen for the product.
6.5 User interface design and implementation
The hardware of the new device was decided to be kept the same as the existing
therapy device NBT and the GUI was the only component that needed to be
redesigned. The GUI design process started in 2012 when an external company was
hired to design the outlook of the software. Before the GUI could be designed, all
functions and tasks related to the system usage needed to be analyzed. The tasks
were linked into a chronological order in the treatment process to make an outline
for the workflow-driven GUI. The screen design started from rough sketch models
that had one main task on each screen. The design and screen contents were further
developed aiming at a modern and easy-to-use GUI.
The design process faced difficulties and the company designing the GUI was
changed two times. In 2015, a software design company was hired to redesign
and complete the GUI. When the treatment workflow was finalized and screen
components were decided, the GUI outlook and color were chosen. Figure 8 presents
four color alternatives from which the darkest design, 8a was chosen.
The GUI design was an iterative process where workflow step screens were
drawn, evaluated and improved according to feedback. Regular review meetings were
attended by the project manager, project assistant, product manager, and graphical
designers. When the screen design was suitable for the workflow step, the screen was
accepted and given to software developers to implement.
Nexstim’s existing software had been implemented using the C++ programming
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language and Microsoft Foundation Class Library (MFC). C++ had been selected for
its excellent performance in real-time calculations required, for example, for E-field
visualization during stimulation. MFC is a C++ library that was used for developing
the Windows-based GUI for the company’s previous products.
MFC was discovered to be too stiff for developing the new workflow-driven GUI,
and thus Qt and Qt Modeling Language (QML) were chosen for the GUI development.
The choice of Qt and QML was reinforced by the fact that they provide a powerful
modern software development framework and support using C++ natively. QML
was chosen alongside Qt as it seemed at certain point that Qt would phase out the
native desktop GUI components and QML was the upcoming primary language for
flexible GUI implementation. However, later Qt continued the development of the
native desktop GUI components normally, side by side with QML.
Advantages of QML considering Nexstim products include the ability to modify
QML’s own GUI components to the needs of unique GUI design, make different
workflow processes for different applications, brand the GUI for different products,
localize GUI for different market areas not only by language but also by layout and
possibility to change from Windows platform into Linux.
The software implementation team included a software architect, senior designer,
designer, and few consultants. The full software implementation was not completed
in the framework of this master’s thesis due to a lack of resources. However, the GUI
and workflow implementation was adequate for conducting a usability evaluation
presented in Section 7.
The user manual and training material were not finished within the time framework
of this thesis. The user manual of the existing therapy device is used as a base
for creating the manual for the new product. The new user manual is going to be
in the form of simple step-by-step instructions for conducting a workflow step. A
mock-up of the software integrated user manual is already implemented, but it is
incomplete as the content is still missing. The integrated manual is displayed in a
web browser styled pop-up window presented in Figure 9. The contextual help is
designed to apply the same texts as the manual, but as the content is missing, the
implementation of contextual help is postponed.
6.6 User interface evaluation
The manufacturer needs to evaluate the user interface through the development
process and after the device is ready to be marketed. The development phase
evaluation was known before as usability verification, but with the new version
of IEC 62366-1:2015 the name changed into formative evaluation. Moreover, the
evaluation of the finished product is now called summative evaluation instead of
usability validation.
6.6.1 Formative evaluation
Formative evaluations are performed through the product development process to
gain valuable information on the usability of the user interface. At the early sate
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Figure 9: The outlook of the software integrated user manual. The manual content
presented in the figure is from the existing NBT device’s manual.
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(a)
(b)
(c)
Figure 10: Example of screens used in the formative evaluations. All images represent
a screen where user sets MRI landmarks to the patient’s MR images. a) is an image
shown to the participants in the concept test held in February 2015, b) is a screenshot
from the UI prototyping software used in the second user test in December 2015, and
c) is a screenshot of the latest prototype used in the usability evaluation in 2019.
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of development, the formative evaluation is performed to gain information about
the design strengths and weaknesses. The assessment conducted at the later state
can help the manufacturer to evaluate the safety and usability of the user interface.
Formative evaluations can be usability tests, cognitive walkthroughs, expert reviews
and other evaluations that will benefit the development of the product.
Nexstim has conducted two user tests with the SNBT user interface. In February
2015, the initial concept of the SNBT software was tested to receive feedback on
the preliminary workflow-driven graphical user interface. The study included 11
participants from six facilities that had from seven months to four years of experience
with Nexstim’s systems. Concept drawings of the GUI were shown and participants
were asked to rate the different aspects of the screen designs. One example of a
concept drawing is presented in Figure 10a.
The user interface of the concept test was developed for a stroke application
and not for the depression application which is now the intended use for the SNBT
software. However, the basic principles of the workflow are the same and thus the
results can be used as input for the current depression and pain applications. The
concept test showed that the workflow orientation and touch screen were convenient
and beneficial changes from the user interface of the existing device.
The second user test was conducted in December 2015 using a UI prototyping
software. The prototyping software is a convenient and quick tool for developing
and testing GUI ideas. At this point in the development process, the appearance
of the software design had evolved from the previous as the company designing the
GUI changed. An example of the GUI design used in this evaluation is presented
in Figure 10b. Six participants from three clinical sites completed seven scenarios
with the prototype software from a laptop without the presence of a TMS system.
The scenarios included multiple real-world tasks that are frequently done in the
treatment protocol. The participant’s interaction with the application was monitored
by the facilitator and note-takers. Audio and on-screen activity were recorded and
keystrokes were tracked and quantified. After completing the tasks, the participants
answered to a questionnaire and were interviewed to get additional feedback.
In the data analysis, successful scenario completion ratio, error-free ratio, and
subjective evaluations were analyzed. In three scenarios out of seven, all participants
were able to complete tasks successfully without help. However, two scenarios resulted
in critical errors and none of the participants were able to complete them. The
error-free ratio was 100% only in two scenarios and all other scenarios had errors
with all participants. In the error-free ratio calculations, all errors were recorded even
though the participant might have recovered from the error by themselves. These
kinds of errors do not necessarily prevent the completion of the scenario but are
frustrating for the user.
While completing the scenarios, participants expressed over two hundred com-
ments about the software. The findings were classified as problems or items that
generated use errors, additional findings impacting functionality, graphics-related
suggestions and positive comments. The findings included, for example, users not
knowing what to do on a screen, failing to locate a certain icon, not understanding
the function of a control and so on. Participants particularly liked 25 features.
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The overall impression was that the new software is user-friendly, streamlined,
well-organized, and intuitive. The participants thought that the workflow guided
process may decrease the learning curve for future users. Users particularly liked
the idea of controlling the application with a touchscreen. Participants appreciated
that they are guided through all necessary steps in the treatment process. Both of
the early user tests gave important feedback from the new GUI and software, and
the results have been exploited in the further development of the product during the
past years.
In 2019, a new user test was conducted for a more advanced user interface. The
methods and results of this study are presented in Section 7.
6.6.2 Summative evaluation
The objective of summative evaluation is to validate the usability of the UI of the
finished product. The assessment is conducted to confirm that the UI enables effective
use and minimizes harmful use errors. The summative evaluation will be performed
for the new product when the software is fully implemented and user manual and
training material have been established.
The summative evaluation will be conducted by performing a usability test where
users are observed while performing tasks using the device. The usability test was
selected as the test method because it is quite easy to conduct, and an expert review
would not be thorough enough to test such a major change in the GUI. Moreover,
expert reviews should not be used when hazard-related use scenarios can arise during
use.
The summative evaluation will be conducted under simulated conditions. The
use environment will be a simulated clinical room and the test will include healthy
subjects acting as patients. The participants will be clinical personnel that are used
to using nTMS devices for the treatment of depression and pain.
Summative evaluations have previously been conducted for Nexstim’s existing
products and thus the focus of the assessment will be to evaluate the usability of the
new GUI and new hardware components, the touch screen and the foot pedal. The
evaluation will include testing both application and the hazard-related use scenarios
recognized in the risk analysis presented in Section 3. The usability test will also
assess if the training material and user manual are perceivable and understandable.
The data collected from the usability test will include performance data and sub-
jective comments. Performance data will be recorded by observing users conducting
tasks on the new device and by recording correct use, use errors, close calls and use
difficulties. The test environment should resemble normal clinical setting as closely as
possible and thus participants should not be asked to think aloud and test personnel
should not make contact with participants.
The subjective data will be collected by interviewing participants after the usability
test. The aim of the interview will be to find out the root causes of any occurred
use errors. The interview questions will also cover the overall impression of the new
product and any possible close calls and use difficulties that were not recorded during
use.
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In the data analysis, potential causes of each use error will be analyzed and all
root causes will be determined. If new use errors, hazards or hazard-related use
scenarios are discovered during the summative evaluation or further development is
otherwise needed, the UE process will be re-entered. If no improvements are needed,
the residual risks of the device will be evaluated according to the risk management
standard ISO 14971.
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7 Usability evaluation
The formative evaluation of the new nTMS product was conducted at the end of
the year 2019 using a functional prototype. The product had evolved significantly
from the last usability studies and thus a new evaluation took place. The aim of
this assessment was to verify the usability of the GUI and gain input for further
development if usability deficiencies were found. The objective was to study whether
the usability goals described in Section 2.4 were met.
7.1 Methods
The usability study evaluated the advanced SNBT prototype using six common
scenarios that were completed by current Nexstim system end-users. The participants
were asked to carry out the most frequent tasks in the depression treatment protocol
as well as troubleshoot some common problematic situations in the environment
representing the actual use conditions.
7.1.1 Test system
The test system was created so that the participating hospital’s existing NBT system
stayed as intact as possible to avoid any technical problems after the usability test.
The test system included a laptop with the latest software version of the new product,
a touch screen, and a foot pedal. The participating hospital’s NBT system patient
chair, camera, digitizer pen, and stimulation coils were used. The test room’s NBT
system display was replaced with the touch screen that was plugged into the laptop
and a power source. The NBT system’s camera wire was detached and an additional
camera wire was connected between the camera and the laptop. A 3D printed head
was used to simulate patient as the prototype could not be used with real patients
yet.
As the study did not include real patients present, TMS and EMG simulators
were used. The TMS simulator creates artificial magnetic pulses that evoke responses
to the EMG simulator. The SNBT software communicates with the simulators and
thus pulses and responses can be displayed on the screen. The TMS and EMG
simulators, foot pedal, RFID reader for head trackers, and touch screen USB were
connected to a USB hub on the laptop. The 3D printed patient head was fixed to the
patient chair neck rest for the length of the test. A camera stand with an attached
smartphone was placed so that the touch screen activities were visible on video. The
test system is presented in Figure 11.
The software version used in the usability test was not fully and had some defects.
All screens in the workflow were not implemented and thus they were passed by with
the help of the test personnel.
7.1.2 Participants
Nine participants from two hospitals participated in the usability study. Participants
were from the user (system operator) and admin user groups described in Section
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Figure 11: The test setup used in the usability evaluation.
6.1.4. Participants included seven nurses, one physician, and one hospital physicist.
Only one physician, instead of the desired two, was able to attend the study due to
time constraints. The use experience with Nexstim systems varied between 5 months
and 15 years. The participant backgrounds are presented in Table 4. All participants
received a short training of the new product and test system before the test started.
The quick training was not as extensive as the clinical training given to the new
users.
Participant Occupation Experience with Nexstim systems
P1 Nurse 1 year
P2 Nurse 8 years
P3 Physician 15 years
P4 Hospital Physicist 4 years
P5 Nurse 4 years
P6 Nurse 4 years
P7 Nurse 4 years
P8 Nurse 2 years
P9 Nurse 5 months
Table 4: Participant information.
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7.1.3 Use scenarios
In the usability test, the participants operated the system in six typical use scenarios
presented in Table 5. All scenarios included two to eight tasks that were selected
because they were the most frequent functions performed in the treatment process or
tasks for solving common problematic situations. The completion of selected tasks
also represented the fulfillment of some of the usability goals. The tasks were selected
from the depression application as it was more familiar for the participants and the
software implementation was more advanced than in the pain application.
Participants received a task sheet presented in Appendix A including all scenarios
and tasks to guide them through the test. The task sheet was provided both in
English and in Finnish. The participants were instructed to read the whole scenario
and list of tasks and ask questions, if they had any, before starting the tasks. While
performing the tasks, participants were instructed to talk aloud. In addition to the
task sheet, the test facilitator asked additional questions that were used to test some
of the usability goals.
In Scenario 1, Create patient, participants needed to conduct eight tasks in order
to create a new patient. Among others, the scenario included tasks for importing
MR images to the system, entering patient information and setting MRI landmarks.
Scenario 2 asked participants to prepare the system before the patient arrives for
their first baseline visit. In Scenario 3, the participants needed to prepare the patient
for treatment by activating a head tracker and aligning the camera so that the tracker
was in the camera’s field of view. Registering the patient’s head and the MR images
to the system were also performed in Scenario 3. The patient’s first baseline session
was conducted in Scenario 4. The baseline session included mapping the patient’s
motor cortex in order to find the representative area of thumb muscles, determining
the stimulation intensity for the treatment, and determining the location where the
treatment would be given. Scenario 5 included preparing the system for a patient’s
3rd treatment session and finally, in Scenario 6, participants gave treatment for the
patient.
Due to time constraints, all participants were not able to complete all scenarios.
Participant 7 completed only scenarios three to eight and participant 8 scenarios two
to eight. Scenarios 1 and 2 were selected to be left out as creating new patients was
not the participating nurses’ duty. The fifth participant could not perform tasks 7
and 8 from the fourth scenario due to technical difficulties with the software. This
scenario also included two additional tasks given by the facilitator. Users needed to
tell the value of the E-field maximum and the EMG response amplitude and describe
where the user was in the workflow process.
7.1.4 Data collection methods
Data was collected by video recording the participants’ actions on the touch screen
while performing the scenarios. This method was selected as it would have been too
difficult to write notes from all user actions as there was only one test personnel
present. During the test, the users were asked to think aloud to enable the recording
of comments and difficulties using the system. After the test, participants filled in a
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Scenario
1 Create patient
2 Prepare for baseline visit
3 Prepare patient and register
4 Conduct baseline
5 Load patient
6 Conduct treatment
Table 5: Use scenarios performed in the usability evaluation.
questionnaire and were interviewed. The questionnaire and interview questions were
translated into Finnish to help with answering.
7.1.5 Data analysis
Data analysis aimed at the quantitative evaluation of the user interface and the
identification of usability problems and safety issues created by the user interface.
The video recordings were analyzed to find out scenario completion ratio, number
and type of errors encountered during each scenario and error-free ratio. Scenario
competition ratio is the proportion of participants able to complete a scenario. Each
scenario required the participant to obtain or input specific data. The scenario was
considered completed when the user had finished the last task of a scenario, indicated
that the goal of the scenario was obtained, or the participant requested and received
guidance from test personnel.
The errors in conducting scenarios were classified into three types. An error was
considered as critical if it produced an incorrect outcome or restrained participant
from continuing the treatment process. Asking for help from the test personnel in
the essential tasks for the treatment process was also seen as a critical error. Another
class of critical errors was incorrect outcomes or asking help in the troubleshooting
tasks that were not mandatory in the treatment process. These faults were called
moderate critical errors (MCE). The third class of misuse was non-critical errors
(NCE) that were deviations from the optimal task completion and were recovered
by the participant, or if they were not detected, they did not result in processing
problems or unexpected results. Questions about the user interface, unrelated to
helping the participant through a task, were considered as comments. Forgetting to
do a troubleshooting task was not considered as an error as they do not block the
workflow process. Some NCEs and minor problems that did not significantly affect
the task completion were marked as difficulties. A difficulty was, for example, extra
clicks on the screen and wandering in the GUI when looking for a function.
Based on the above-mentioned error classification and the frequency participants
made those errors, a severity classification was made for each problem the participants
encountered during the usability test. The highest class of severity was Class 4 in
which the usability problems generated possible risk for the system user or the patient.
Class 3 severity was assigned to critical errors as they prevented the participant
from correctly completing the task. Moderate critical errors and non-critical errors,
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made by over 25% of participants, were in severity Class 2. The lowest class of
severity, Class 1, was assigned to NCE and MCEs that were made by less than 25%
of participants and difficulties experienced by over 25%. The severity classification is
presented in Table 6.
Severity Explanation
Class 4 Usability problems that generate possible risk
for the user or patient.
Class 3 Critical errors in essential tasks in the treat-
ment process that prevent correct use.
Class 2 MCEs and NCEs made by over 25% of par-
ticipants
Class 1 NCEs and MCEs made by less than 25% of
participants and difficulties experienced by
over 25% of participants.
Table 6: Severity classification for problems encountered during the usability test.
The post-task questionnaire and interview answers were analyzed qualitatively to
find out the users’ opinions and features participants generally liked and disliked.
7.2 Results
7.2.1 Scenario completion
Scenario 1, where participants needed to import MR images and create a new patient,
was performed only by seven participants due to time constraints. From those seven
participants, four were able to complete the scenario successfully without critical
errors and none completed the scenario error-free. The scenario completion and
error-free ratios for all scenarios are presented in Table 7. Critical errors were faced
in task 1. Import MR images, task 3. Optimize MRI and a troubleshooting task
7. Set point of interest (POI). Further analysis of these problems is presented in
Section 7.2.2 Identified usability findings. Scenario 1 resulted in seven critical errors,
6 moderate critical errors, 15 non-critical errors and 6 difficulties.
In scenario 2, participants needed to open previously created patient data and
prepare the system for the patient’s first baseline visit. All eight participants who
performed the scenario were able to complete the scenario successfully and error-free.
The usability of the GUI when preparing the patient for the baseline was tested
in scenario 3. Eight out of nine participants were able to perform this scenario
successfully and error-free. The critical error was made when one participant didn’t
understand what align camera meant. The participant making this error was a
physician that seldom performs this step in the treatment process.
The most difficult scenario was the fourth one, where participants needed to
map the hand area, determine MT, and create a target for therapy. The scenario
completion ratio was only 2/9 and error-free ratio 1/9. The biggest problem was that
the participant did not know what to do in each task. Task 4, perform preliminary
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coil orientation map, created the most errors as participants thought they were
supposed to determine the motor threshold in this step. Five out of six participants,
who remembered to do task 3, were able to find the coil expiration date from the GUI
quite easily. The scenario included two additional tasks given by the test personnel
that were not in the task sheet. All users were able to see the value of the E-field
maximum and EMG response amplitude when standing next to the patient. The
test personnel forgot to ask the participants to perform the second additional task.
The task would have been to describe where in the workflow process the user was. In
total, scenario 4 yielded in 17 critical errors, one MCE, 15 NCEs, and 8 difficulties.
The fifth scenario, where participants needed to prepare the system for patients
3rd treatment, had only one critical error and one non-critical error. The completion
ratio was 8/9 and error-free ratio 7/9.
In scenario 6, participants gave treatment for a patient. Both the completion
ratio and error-free ratio were 4/9. However, only one error was made in the essential
tasks of the treatment process. A participant tried to pause the treatment by clicking
different parts of the GUI causing a non-critical error. Troubleshooting task 3, adjust
camera orientation with the help of the alignment tool, yielded the most errors as
the participants could not find the alignment tool. In total, scenario 6 yielded in 0
critical errors, 5 MCE, 4 NCEs and 4 difficulties.
Scenario Completion ratio Error-free ratio
1 Create Patient 4/7 0
2 Prepare for baseline visit 8/8 8/8
3 Prepare patient and register 8/9 8/9
4 Conduct baseline 2/9 1/9
5 Load patient 8/9 7/9
6 Conduct treatment 4/9 4/9
Table 7: Completion ratio and error-free ratio for each scenario.
7.2.2 Identified usability findings
The data analysis resulted in the discovery of a total of 17 usability findings presented
in Appendix B. Most problems arose from legibility issues regarding instructions in
the workflow step screens and pop-up windows and from the accessibility of functions.
None of the identified deficiencies were classified as the severity Class 4 implying
possible risk for the user or patient.
Six usability findings were given Class 3 severity as they created critical errors
that prevented correct use in the treatment process. One of these problems was
created in scenario 4 task 1 where participants needed to map the patient’s motor
cortex. The screen header, "Preliminary Mapping", was not informative enough for
the participants to know what to do. The test personnel needed to explain the task
which created a critical error.
In severity class 2, five usability findings were identified. The problems were
found as participants tried to perform tasks in incorrect screens or pop-up windows
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and they could not find functions. These problems were faced by over 25% of the
participants. For example, users tried to set a POI in a pop-up where the user can
change the 3D head and MRI scan properties. The two windows were said to be too
similar and thus users mixed them up. Participants also had problems finding the
tools for aligning the camera and viewing information about the used stimulating
coil.
Less frequent problems were grouped into severity Class 1. These six deficiencies
were created by a lack of training and ambiguous features in GUI design. When
reviewing maps, participants had difficulties selecting a stimulus from a table. The
table had different colors for rows that were highlighted and selected. The participants
thought that a row was selected by simply highlighting it and not by selecting the
radio button. Figure 12 presents the map review screen with one highlighted row.
Figure 12: Review Mapping screen with first stimulus highlighted. User can select a
stimulus by tapping the select radio button on the right side of the stimulus table.
A GUI design deficiency was found as one participant wanted to set her own POI
instead of using the DLPFC depression therapy POI that the software had suggested.
The user could not find the tab where she could have created her own POI. The POI
pop-up with the DLPFC-tab open is presented in Figure 13. The POI tab could have
been opened by tapping the dim orange text link, "POI", above the row describing
the DLPFC POI information.
7.2.3 Questionnaire and interview
The questionnaire included a question and 10 claims that participants needed to
rate after using the system. The question asked how likely the participant would
recommend the software used today to their colleagues on a scale from 0 to 10, 0
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Figure 13: POI pop-up window with DLPFC-POI-tab open. User can open POI-tab
by tapping the dim orange text "POI" indicated with a red arrow.
meaning "highly unlikely" and 10 meaning "extremely likely". The results show that
participants would recommend the SNBT software to their colleagues very likely
with an average score of 9.
The questionnaire claims and answers are presented in Table 8. The results
show that the software was well-liked. Participants strongly agreed that they would
enjoy the frequent use of the software and that most people would learn to use it
quickly. Users agreed that the product is easy to use, and that various functions
were well integrated. Participants disagreed with the claims that the software is
complex, inconsistent, cumbersome to use and that users would need to learn a lot
before using the software independently. The largest variance in the questionnaire
resulted from the claim about needing technical support when using the system.
Three participants strongly disagreed with the claim and three somewhat agreed.
Users didn’t feel confident nor insecure when using the system
In the interview, participants said that the GUI is modern and more pleasant
than the NBT software they are using now. Users particularly liked that the software
guides them through the treatment process. The touchscreen, ability to move the 3D
head with gestures and the new pedal that can be used with bigger shoes received
praise.
Most users said that it is hard to detect any annoying features during such a so
short use. Two participants thought the sounds in the registration were annoying.
The sound when a landmark is set should be clearer and there should not be a loud
cue after the 3-point registration as the registration process is still not ready. Few
participants said that they had problems finding functions in the new software as
they looked for the same icons and buttons as in the software they are using now.
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Usability Claims StronglyDis-
agree
Somewhat
Disagree
Neu-
tral
Somewhat
Agree StronglyAgree
1. I think I would like to use this
software frequently. - - - 3 6
2. I found the software
unnecessarily complex. 2 5 1 1 -
3. I thought the software was
easy to use. - - 1 5 3
4. I think that I would need the
support of a technical person to
be able to use this system.
3 1 2 3 -
5. I found the various functions
in this software were well
integrated.
- - 2 5 2
6. I thought there was too much
inconsistency in this software. 1 7 1 - -
7. I would imagine that most
people would learn to use this
software very quickly.
- - - 4 5
8. I found the software very
cumbersome to use. 4 5 - - -
9. I felt confident using the
software. - 1 6 1 1
10. I need to learn a lot of things
before I could get going with this
software.
4 4 1 - -
Table 8: Questionnaire scores. Each row presents a claim and number of participants
answering the claim according to the column header.
However, the participants said that they would perform better if they had a chance
to do the test again as they already learned a lot when using the system for the first
time.
Some terminology used in the software were considered hard to understand. The
participating nurses said that most difficult terms were in the parts of the workflow
where a physician would usually be present and thus nurses would not need to
understand them. It was noted that some screen headers and button texts could be
more informative.
Participants emphasized that the software is very easy to use and that they would
learn to use it quickly. Most of the participants thought that they could train a
colleague after using the system a few times to treat patients. When asking would
the participants like to have their possible new device to be Nexstim’s current NBT
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or the new SNBT, seven out of nine told they would like to have SNBT. One user
was unsure, and one explained that they would probably need to have a more flexible
system for their research purposes.
7.2.4 Meeting the usability goals
One aim of the formative evaluation was to study whether the usability goals were
reached. Result analysis discovered that three out of six goals were met. Goal 2 was
reached as users were able to use the system from two distances. Participants could
hear and see information standing next to the patient as well as standing close to
the screen. Goal 4 was met as all users were able to describe the treatment quality
and accuracy in the treatment summary screen. Goal 6, less downtime, was met as
participants were able to find information about the coil expiration date.
Goal 1 was not met as users needed help on what to do next. This goal can be
met by better wording in the screens and by adding training. Goal 5, it is clear to
the user where one is in the treatment process, was not met as the test personnel
forgot to ask the users to describe the screen they were in in scenario 4. Goal number
3, ability to conduct treatment session in less than one hour, was not tested in the
usability test as fulfilling this goal requires more experience with the new system
and this was the first time the users operated the system. Testing goal number 3
would also have needed real patients present.
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8 Discussion
The regulation of medical devices is a truly complicated field and mastering it requires
a lot of effort and experience. The legal text of regulations is hard to comprehend
and most rules have exceptions and repealing rules for special cases. This master’s
thesis described only the outline of medical device regulation in the target market
areas of the new device. The regulation and device approval processes have been
considered to be more strict and less efficient in the US than in Europe. Now, as
new requirements have been added to the MDR, it will be interesting to see if the
approval of new devices will become more difficult and take more time.
The usability engineering process was developed for the company to fulfill the
requirements of the IEC 62366-1:2015 usability standard. The standard operating
procedure (SOP) for the process was approved by the head of QA&RA and taken as
part of the company’s quality system. The usability engineering process was applied
and required product development activities and documents were delivered. The
process was proven to be adequate in analyzing the usability of the new product.
Especially task analysis was found to be an excellent method for analyzing possible
safety-related use error. Task analysis generated new use errors that had not been
found in risk analysis of the company’s previous devices.
The developed UE process SOP is a document containing a list of deliverable
documents and requirements for their content. The SOP could be further developed
by adding specific instructions on how the process was conducted for the new device
and specifying what methods have proven to be suitable for the company. For
example, task analysis and severity assessment of usability findings in the formative
evaluation could be added to the SOP.
The usability evaluation gave important information about the new product
and the usability of the GUI. In general, the device received great feedback and
participants enjoyed using the system. Most tasks the participants performed during
the evaluation were completed successfully. It was determined that the most frequent
tasks in the treatment process were easier to conduct than the tasks that participants
seldom did.
The evaluation resulted in some usability findings that were mostly due to bad
wording choices in the screens and pop-up windows and lack of user training. Some
findings were made about functions being difficult to find due to ambiguous GUI
components. Problems using the system might also have aroused from the fact that
it was the very first time the participants used the system and they tried to find
similar icons and buttons as in the existing system they had used before. The test
results may have been better if the participants had had an earlier contact with the
system. Many participants thought that they could perform better if they had the
chance to do the test again.
Most of the usability findings could be handled by rephrasing the screen headers
and instruction texts more carefully. The headers should have a clear description
of what the user should do in the screen. The training given before use should
emphasize the new GUI components and differences compared to the existing devices
the participants have used. The GUI design for the tabs was found confusing and a
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redesign should be considered.
The test setup was practical for the usability evaluation and could easily be
regenerated for future tests. The software version used was adequate enough for the
assessment although some software defects contributed to the use errors. Furthermore,
a more advanced software version would certainly give more representative usability
data. One great improvement would be the implementation of the EMG and relevant
graphs. Interpretation of EMG responses is an important factor during the motor
cortex mapping and the usability of graphs should be carefully studied.
The test participant profile was quite homogeneous as seven out of the nine
participants were nurses. It would have given more realistic data if more physicians
and hospital physicists would have participated as some duties in the treatment
process are typically assigned only for them. Prior experience using Nexstim’s systems
varied greatly among participants, but there were no significant differences in task
completion between different backgrounds.
The scenarios and tasks that were selected for the usability evaluation were the
ones that are normally done in the treatment process. The task descriptions in the
task sheet could have been more informative. The descriptions were kept succinct to
not give too much direction for completing the tasks. Another and possibly superior
solution compared to giving more instructions would be to reword the screen headers
as previously suggested.
Video recording screen activities while participants performed the tasks was
discovered to be an appropriate data gathering method. Going through and tracking
all use errors and comments from the over five hours of video recording was a time-
consuming but more precise method than writing notes while observing participants
performing the tasks would have been. Quantitative analysis of usability is quite
difficult, but the selected methods were deemed satisfactory. Severity classification
for usability findings was a great method for assessing further developments regarding
the GUI components.
In the future, a new usability evaluation should be performed with a more
advanced prototype where the usability findings discovered in this thesis have been
minimized. The assessment should be performed in the US as it is the main target
area for the new product. The training given before the test should be more extensive
and focus on certain new GUI components and differences compared to the existing
devices. As all usability goals were not met in the usability evaluation presented in
this thesis, the usability goals should be retested. The test scenarios should include
testing the pain application as the workflow is more flexible than in depression
application and therefore it might be harder to use.
The summative evaluation presented in Section 6.6.2 should be performed when
the new device is ready for production. If the final usability assessment is successful
and no new hazard-related use scenarios are discovered, the usability of the device is
proven to be adequate. However, the evaluation of the product does not end when
the device is released to the marked as it needs to be continuously evaluated in
post-market surveillance.
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9 Summary
The number of medical devices has increased rapidly over the years and they have
become an essential part of health care. The safety and effectiveness of medical
devices are ensured by laws and regulations that are overseen by authorities such as
the Food and Drug Administration (FDA) in the United States (US).
In 2017, the European Parliament and Council published a new medical device
regulation (MDR) that repealed the old medical device directives. Considering
usability, the regulation states that the risks related to use error should be eliminated
or reduced as far as possible. Complex user interfaces (UI) that have inadequate
usability can cause use errors that can possibly lead to dangerous situations.
The goal of this master’s thesis was to research medical device regulation, update
the quality system of a company to the level of the new MDR, develop an usability
engineering (UE) process according to usability standards and apply the process for
a new navigated transcranial magnetic stimulation (nTMS) device.
The regulation of medical devices was discovered to be a complicated field as
all countries have their own laws and regulations that differ from each other. In
all studied regulations, medical devices are divided into risk-based classes and the
required proof of the safety and effectiveness varies between classes. The manufacturer
of the device needs to demonstrate safety before the product can be released to the
market.
This master’s thesis renewed the quality management system (QMS) of an nTMS
device manufacturing company to comply with the usability requirements of the
MDR. The QMS was updated by compiling a standard operating procedure (SOP) for
conducting the UE process described in the harmonized standard IEC 62366-1:2015.
The UE process was applied according to the requirements of the usability standard.
The UE process resulted in finding several use errors and hazards that could
affect the safety of the patients or the users. The hazard-related use errors were
further analyzed in risk analysis and the severity of each risk was assessed. Previous
formative evaluations were described briefly and an outline for the final summative
evaluation was presented.
The usability evaluation of the new product conducted at the end of the year
2019 was presented more thoroughly. The goal of the assessment was to verify the
usability of the graphical user interface (GUI) and test the fulfillment of usability
goals. In the study, nine current nTMS device users operated the new system in
the most frequent tasks in treatment in a realistic clinical use environment. The
data analysis identified usability deficiencies by tracking the scenario completion
ratio, the number and type of use errors, and the error-free ratio. The severity of
the usability findings was assessed with a four-point scale taking into account the
type and frequency of the use errors.
The evaluation resulted in the identification of 17 usability findings that were
mostly created by unclear instruction texts and ambiguous GUI components. None
of the findings generated possible harm for the user or the patient but less severe
findings were discovered. Three out of the six usability goals were met.
The developed UE process was successful, but the process could not be finished
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as the product did not get finished in the time frame of this thesis. In the future,
the UE process should be continued by performing a new formative evaluation with
a further developed system and finalized by conducting a summative evaluation for
the production equivalent system.
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A Use scenarios and tasks
The Table below presents the task sheet given to the participants in the usability
test. Tasks marked with an asterisk (*) are additional troubleshooting tasks that are
not mandatory in the workflow of treatment.
Scenario Task
1. You have a new patient
coming tomorrow. Please make
preparations as far as makes
sense today. You have the name
of the patient and a USB drive
with patient’s MR images.
Patient name: Gustaf Järnefelt.
1. Import MRI
2. Create Patient
3. Optimize MRI
4. Enter Patient Infiromation
5. Select depression application
6. Set MRI landmarks
7.* Set POI to hand knot (POI = point of
interest, known as therapy target in NBT)
8. Go to home screen (Save and Quit)
2. The patient you prepared
yesterday is coming in 10 min or
less. Start preparing for the first
baseline visit. Patient name:
Gustaf Järnefelt
1. Open existing patient
2. Open treatment plan created earlier
3. Add new baseline
4. (End at EMG page)
3. Patient Gustaf Järnefelt
arrives for his baseline mapping
session. Starting at the EMG
page, work through the screens as
if you are setting up the
disposables, and complete both
landmark and advanced
registration. The scenario is
completed once you tell me your
registration accuracy
(Start at EMG screen)
1. Activate Head Tracker
2. Align camera
3. Perform registration
4. Tell the registration accuracy
4. Patient Gustaf Järnefelt has
arrived for a mapping session.
You have already set up the
patient and completed
registration. Starting at the
Advanced Registration page,
complete a mapping session. The
scenario is completed once you
can view your treatment target
on the Depression target
summary screen.
(Start at advanced registration screen)
1. Perform preliminary mapping (give max
15 pulses)
2. Review the map and select the best pulse
3.* Check the expiration date of the coil
4. Perform preliminary coil orientation map
5. Review the map and select the best pulse
6. Determine MT
7. Set Depression target
8. (End at Depression target summary screen)
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5. Patient Mikko Mallikas is
coming in 10 min or less for their
3rd treatment session. Start at
the Home screen and end once
you have gone as far as possible
without Mikko Mallikas present.
1. Locate existing patient Mikko Mallikas
2. Select Start 3rd treatment session
6. Patient arrives for their 3rd
treatment session. You have
already set up the patient and
completed registration. Work
through a treatment session
starting from the advanced
registration page.
(Start at advanced registration)
1. Continue to therapy
2. Select rTMS file for the treatment and
continue with the previous MT
3.* Adjust camera orientation with the help
of the alignment tool
4. Start therapy (let the therapy run for a
minute)
5. Pause therapy
6. Stop therapy
7.* Describe how accurate the therapy was
8. Go to home screen
Table A1: Task sheet given to the participants in the usability evaluation.
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B Usability findings
The table below presents the findings discovered in the usability evaluation divided
for each severity level. The task column presents the scenario (S) and the task (T)
the finding was detected in.
Severity level 1
None
Severity level 2
# Task Finding Supportive evidence Note
1. S4
T1
The users did not
understand what
to do in prelimi-
nary mapping
The users did not know if they
had to use the stimulation coil,
the users asked help
2. S4
T4
The users as-
sumed that
they needed to
determine MT
although they
were in map
coil orientation
screen
The users attached the coil to the
holder and walked to the system
in order to start the MT deter-
mination, the users had to be in-
structed to rotate the coil and give
stimuli
The coil ori-
entation map
has been re-
moved from the
application
3. S1
T3
The users did not
know what opti-
mize means
The users asked what they were
supposed to do
4. S5
T2
A user did not
find "START
3RD TREAT-
MENT" button
The user tapped other components
on the screen and the test person-
nel needed to instruct the user
Only one partic-
ipant faced this
problem
5. S1
T1
The users did not
find their way to
import MRI be-
cause the USB
flash drive was
not connected
The users went to "Export MRI"
screen and later to Patient Work
The users who
had connected
USB went
straight to
import MRI
6. S3
T2
A user did not
understand what
align camera
meant
The test personnel needed to in-
struct participant to move the
camera to the target
The problem was
faced only by
one participant
who usually does
not prepare the
patient for the
treatment
Severity level 3
Task Finding Supportive evidence Note
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7. S4
T2
The user thought
they could select
pulse already
on the mapping
screen
The users reviewed and high-
lighted pulses already in the map-
ping screen
Software defect:
highlighting
pulses should
not be available
in the mapping
screens
8. S1
T7
The user thought
they could set
POI in adjust
overlay
The users opened the adjust over-
lay to peel the 3D head, moved
the crosshair to the location they
wanted to set the POI to, and
pressed "APPLY" button. How-
ever, the POI was not set as the
users were in the wrong pop-up.
9. S6
T3
The users did
not find the align
camera overlay
5/9 of the participants needed help
to find the overlay
10. S4
T3
The users did not
find the coil infor-
mation overlay
The users tried to find the overlay
in the Menu
Only one partici-
pant asked help
11. S1
T8
The users did not
go to the home
screen
The users tapped “SAVE AND
CONTINUE” button instead of
”SAVE AND CLOSE”
Severity level 4
Task Finding Supportive evidence Note
12. S4
T7
A user was not
able to find
the POI tab in
the POI over-
lay when the
DLPFC-POI tab
was open
The user asked help Only one par-
ticipant tried to
change tabs
13. S4
T7
The users
thought therapy
target was given
by setting a
DLPFC-POI
and not by using
the coil
The users wandered in the "Set
target" screen not sure how to con-
tinue
14. S1
T6
The browsing of
the MRI slices
was difficult
The users changed the slices one
by one by tapping arrows in MRI
slice view
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15. S1
T6
The users had
difficulties select-
ing a stimulus
The users thought highlight was
already select and the users wan-
dered in the GUI trying to find
the select radio button.
16. S1
T7
The users had
difficulties find-
ing the "CRE-
ATE POI" but-
ton.
The user wandered in the GUI try-
ing to find a way to create the POI
17. S4
T2
A user had dif-
ficulties finding
the pause button
The user tapped several places in
the GUI to pause the treatment
before finding pause button
Only one partic-
ipant faced this
problem
Table B1: Usability findings discovered during usability evaluation presented in
Section 7.
